ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...
Add Yahoo as a preferred source to see more of our stories on Google. A subset of FreeStyle Libre 3 plus sensors may provide incorrect low glucose reading, Health Canada says. (Brian Morris/CBC - ...
Health care technology company Abbott has recalled certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring systems because the sensors are displaying incorrect glucose ...
Add Yahoo as a preferred source to see more of our stories on Google. FreeStyle Libre 3 sensor by Abbott Image by Adobe Medical device giant Abbott announced on Sunday that it is recalling ...
Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's issuing a voluntary medical device correction for some of its FreeStyle ...
Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also ...
This is now a Class I recall, meaning that the use of these continuous glucose monitoring systems could cause serious health consequences or death. Anna Gragert (she/her/hers) was previously the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results